Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/33895
Title: | Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial | Authors: | Banning, Amerjeet S. Adriaenssens, Tom Berry, Colin BOGAERTS, Kris Erglis, Andrejs Distelmaier, Klaus Guagliumi, Giulio Haine, Steven Kastrati, Adnan Massberg, Steffen Orban, Martin Myrmel, Truls Vuylsteke, Alain Alfonso, Fernando Van de Werf, Frans Verheugt, Freek Flather, Marcus Sabate, Manel Vrints, Christiaan Gershlick, Anthony H. |
Issue Date: | 2021 | Publisher: | EUROPA EDITION | Source: | EuroIntervention, 16 (15) , p. E1227 -E1236 | Abstract: | Aims: Cardiogenic shock (CGS) occurs in 6-10% of patients with acute coronary syndromes (ACS). Mortality has fallen over time from 80% to approximately 50% consequent on acute revascularisation but has plateaued since the 1990s. Once established, patients with CGS develop adverse compensatory mechanisms that contribute to the downward spiral towards death, which becomes difficult to reverse. We aimed to test in a robust, prospective, randomised controlled trial whether early support with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides clinical benefit by improving mortality and morbidity. Methods and results: The EURO SHOCK trial will test the benefit or otherwise of mechanical cardiac support using VA-ECMO, initiated early after acute percutaneous coronary intervention (PCI) for CGS. The trial sets out to randomise 428 patients with CGS complicating ACS, following primary PCI (P-PCI), to either very early ECMO plus standard pharmacotherapy, or standard pharmacotherapy alone. It will be conducted in 39 European centres. The primary endpoint is 30-day all-cause mortality with key secondary endpoints: 1) 12-month all-cause mortality or admission for heart failure, 2) 12-month all-cause mortality, 3) 12-month admission for heart failure. Cost-effectiveness analysis (including quality of life measures) will be embedded. Mechanistic and hypothesis-generating substudies will be undertaken. Conclusions: The EURO SHOCK trial will determine whether early initiation of VA-ECMO in patients presenting with ACS-CGS persisting after PCI improves mortality and morbidity. | Notes: | Banning, AS (corresponding author), Glenfield Hosp, Dept Cardiol, Groby Rd, Leicester LE3 9QP, Leics, England. amerjeet.banning@doctors.org.uk |
Other: | Banning, AS (corresponding author), Glenfield Hosp, Dept Cardiol, Groby Rd, Leicester LE3 9QP, Leics, England. amerjeet.banning@doctors.org.uk | Keywords: | ACS/NSTE-ACS;acute heart failure;cardiogenic shock;depressed left ventricular function | Document URI: | http://hdl.handle.net/1942/33895 | ISSN: | 1774-024X | e-ISSN: | 1969-6213 | DOI: | 10.4244/EIJ-D-20-01076 | ISI #: | WOS:000617275300011 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
author version.pdf | Peer-reviewed author version | 1.01 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
58
checked on Oct 12, 2024
Page view(s)
58
checked on Sep 7, 2022
Download(s)
10
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.